Phase I Trial of Temozolomide
Author Information
Author(s): E.S. Newlands, G.R.P. Blackledge, J.A. Slack, G.J.S. Rustin, D.B. Smith, N.S.A. Stuart, C.P. Quarterman, R. Hoffman, M.F.G. Stevens, M.H. Brampton, A.C. Gibson
Primary Institution: Charing Cross Hospital
Hypothesis
Does temozolomide exhibit effective anti-tumor activity with manageable toxicity in patients with advanced cancer?
Conclusion
Temozolomide shows clinical activity in melanoma and gliomas with manageable side effects.
Supporting Evidence
- Temozolomide was administered to 51 patients with advanced cancer.
- Clinical activity was observed in melanoma and gliomas.
- The recommended dose for Phase II trials is 150 mg/m2 for 5 days.
- Patients tolerated the drug well with manageable side effects.
- Responses included complete and partial responses in melanoma and mycosis fungoides.
Takeaway
Temozolomide is a new cancer drug that can help some patients with melanoma and brain tumors, and it's easier to take than older drugs.
Methodology
Patients with advanced cancer were given temozolomide in escalating doses, both intravenously and orally, to assess safety and effectiveness.
Limitations
The study was limited by the small sample size and the focus on specific cancer types.
Participant Demographics
Patients had advanced cancer refractory to standard therapy, with a mean age of 52 years.
Want to read the original?
Access the complete publication on the publisher's website